Agilent Technologies kooperiert mit Virscidian zur Integration von OpenLab CDS und Analytical Studio

Reuters

Feb 03

Agilent Technologies kooperiert mit Virscidian zur Integration von OpenLab CDS und Analytical Studio

Agilent Technologies Inc. und Virscidian LLC haben eine erweiterte Zusammenarbeit bekannt gegeben, um die Interoperabilität zwischen Agilent OpenLab CDS und Virscidian Analytical Studio zu verbessern. Ziel der Partnerschaft ist es, Wissenschaftlern einen nahtlosen Zugriff auf Chromatographiedaten zu ermöglichen und hochdurchsatzfähige Arbeitsabläufe, einschließlich der Aufreinigung, effizienter zu gestalten. Die Integration beider Plattformen soll insbesondere in der Pharma- und Biopharmabranche die Produktivität in der Wirkstoffforschung und -entwicklung steigern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608269876"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608269876\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608269876?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 20:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608269876","market":"us","top_or_hot":-1,"title":"Agilent Technologies kooperiert mit Virscidian zur Integration von OpenLab CDS und Analytical Studio","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agilent Technologies kooperiert mit Virscidian zur Integration von OpenLab CDS und Analytical Studio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agilent Technologies Inc. und Virscidian LLC haben eine erweiterte Zusammenarbeit bekannt gegeben, um die Interoperabilität zwischen Agilent OpenLab CDS und Virscidian Analytical Studio zu verbessern. Ziel der Partnerschaft ist es, Wissenschaftlern einen nahtlosen Zugriff auf Chromatographiedaten zu ermöglichen und hochdurchsatzfähige Arbeitsabläufe, einschließlich der Aufreinigung, effizienter zu gestalten. Die Integration beider Plattformen soll insbesondere in der Pharma- und Biopharmabranche die Produktivität in der Wirkstoffforschung und -entwicklung steigern.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agilent Technologies kooperiert mit Virscidian zur Integration von OpenLab CDS und Analytical Studio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgilent Technologies kooperiert mit Virscidian zur Integration von OpenLab CDS und Analytical Studio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-03 20:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agilent Technologies kooperiert mit Virscidian zur Integration von OpenLab CDS und Analytical Studio\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agilent Technologies Inc. und Virscidian LLC haben eine erweiterte Zusammenarbeit bekannt gegeben, um die Interoperabilität zwischen Agilent OpenLab CDS und Virscidian Analytical Studio zu verbessern. Ziel der Partnerschaft ist es, Wissenschaftlern einen nahtlosen Zugriff auf Chromatographiedaten zu ermöglichen und hochdurchsatzfähige Arbeitsabläufe, einschließlich der Aufreinigung, effizienter zu gestalten. Die Integration beider Plattformen soll insbesondere in der Pharma- und Biopharmabranche die Produktivität in der Wirkstoffforschung und -entwicklung steigern.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGND","symbol_name":"Ligand Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL96sfyR:1","article_id":"2608269876","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608269876","pubTimestamp":1770123454,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGND":"Ligand Pharmaceuticals Inc.","LU1543694498.USD":"法巴水资源基金RH MD Dis","BK4588":"碎股","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0566484027.USD":"安本美国小盘成长股","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","BK4007":"制药","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4121":"生命科学工具和服务","LU2041044095.USD":"Blackrock Circular Economy A2 USD","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4567":"ESG概念","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","BK4585":"ETF&股票定投概念","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","BK4139":"生物科技","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","A":"安捷伦科技","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC"},"translate_title":"安捷伦科技与Virscidian合作整合OpenLab CDS和Analytical Studio","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":0.9,"A":0.9},"content_text":"Agilent Technologies kooperiert mit Virscidian zur Integration von OpenLab CDS und Analytical Studio\n    \n\n        Agilent Technologies Inc. und Virscidian LLC haben eine erweiterte Zusammenarbeit bekannt gegeben, um die Interoperabilität zwischen Agilent OpenLab CDS und Virscidian Analytical Studio zu verbessern. Ziel der Partnerschaft ist es, Wissenschaftlern einen nahtlosen Zugriff auf Chromatographiedaten zu ermöglichen und hochdurchsatzfähige Arbeitsabläufe, einschließlich der Aufreinigung, effizienter zu gestalten. Die Integration beider Plattformen soll insbesondere in der Pharma- und Biopharmabranche die Produktivität in der Wirkstoffforschung und -entwicklung steigern.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on February 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}